News

The initial studies with rabies VLP vaccine demonstrated that two doses of one or four micrograms induced protective levels of neutralizing antibodies in a mouse model. The company

The new kits will allow pharmacists to dispense the compounded prescriptions containing widely used proton pump inhibitors (PPIs). FIRST products will save dispensing time, and can be compounded

The EYLEA (aflibercept) injection was approved by the Food and Drug Administration for the treatment of neovascular (wet) age-related macular degeneration (AMD). Macular degeneration is diagnosed as either

Both the companies have entered into a strategic partnership to deliver a drug candidate. The long-term collaborative project includes three additional specific milestone targets. Hengrui global R&D president

The company will begin marketing and distributing Biocalth products throughout the US and expanding its revenue opportunities in the bone health and joint health market. The combined businesses

CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Clovis, in partnership with Avila Therapeutics, designed

Trimesta is an oral estriol designed for treating relapsing-remitting MS and for cognitive dysfunction in MS, both in female patients, and has been approved throughout Europe and Asia

The Filgrastim study is intended to assess the efficacy and safety of Sandoz’s biosimilar filgrastim versus Amgen’s Neupogen in breast cancer patients eligible for myelosuppressive chemotherapy treatment. The

The new product line will utilize G-Con Manufacturing’s novel modular, mobile clean-room pods and SSB’s broad single-use and reusable product portfolio to create a totally integrated production process